前列腺素E2 - CAS:363-24-6 - CAS号查询_生物试剂_化学试剂_分析试剂

中文名称:	前列腺素E2
英文名称:	Prostaglandin E2
别名:	地诺前列酮 PGE2
CAS No:	363-24-6	分子式:	C₂₀H₃₂O₅	分子量:	352.47
CAS No:	363-24-6
分子式:	C₂₀H₃₂O₅
分子量:	352.47
MDL:	MFCD00077861	EINEC:	206-656-6
EINEC:	206-656-6

安全技术说明书(PDF) MSDS(PDF) 点击下载技术规格说明书(PDF) 点击下载产品说明书(PDF)

P70039 前列腺素E2 ≥97%(HPLC) (psaitong)

相关产品

半胆碱-3
CAS No：312-45-8
1,2-双(2-氨基苯氧基)乙烷-N,N,N',N'-四乙酸四乙酯
CAS No：73630-07-6
BAPTA 四钾盐
CAS No：73630-08-7
BAPTA 四甲酯
CAS No：125367-34-2
吩嗪硫酸乙酯
CAS No：10510-77-7
亚精胺
CAS No：124-20-9

包装规格：

1mg 5mg 25mg 100mg in glass bottle

溶解性：

溶于DMSO(50mg/mL)

产品描述：

基本信息

产品编号：	P70039
产品名称：	Prostaglandin E2
CAS:	363-24-6	储存条件	粉末	-20℃	三年

分子式：	C20H32O5		溶于液体	-80℃	6个月
分子量	352.47			-20℃	1个月
化学名：	(5Z,11alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid
Solubility (25°C)：
体外:	DMSO	50 mg/mL (141.856 mM)
	Ethanol	50 mg/mL (141.856 mM)
	Water	Insoluble
体内(现配现用):	1:请依序添加每种溶剂：10% DMSO-40% PEG300-5%-Tween 80 -45% saline,Solubility:≥2.5mg/mL(7.09 mM); Clear solution
	此⽅案可获得 ≥ 2.5 mg/mL (7.09 mM，饱和度未知) 的澄清溶液。以 1 mL ⼯作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加⼊ 50 μ L Tween-80，混合均匀；然后继续加⼊ 450 μL ⽣理盐⽔定容⾄ 1 mL。
	2:请依序添加每种溶剂:10% DMSO-90% (20% SBE-β-CD in saline),Solubility: ≥ 2.5 mg/mL (7.09 mM); Clear solution
	此⽅案可获得 ≥ 2.5 mg/mL (7.09 mM，饱和度未知) 的澄清溶液。以 1 mL ⼯作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD ⽣理盐⽔⽔溶液中，混合均匀。
	3:请依序添加每种溶剂:10% DMSO-90% corn oil,Solubility: ≥ 2.5 mg/mL (7.09 mM); Clear solution
	此⽅案可获得 ≥ 2.5 mg/mL (7.09 mM，饱和度未知) 的澄清溶液，此⽅案不适⽤于实验周期在半个⽉以上的实验。以 1 mL ⼯作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL ⽟⽶油中，混合均匀。
＜1mg/ml表示微溶或不溶。
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。

制备储备液

浓度溶液体积质量	1mg	5mg	10mg
1 mM	2.8371 mL	14.1856 mL	28.3712 mL
5 mM	0.5674 mL	2.8371 mL	5.6742 mL
10 mM	0.2837 mL	1.4186 mL	2.8371 mL
50 mM	0.0567 mL	0.2837 mL	0.5674 mL

生物活性

产品描述	一种生物活性最强的前列腺素，可诱导宫颈成熟和分娩，介导缓激肽诱导的血管舒张，调节腺苷酸环化酶。过表达环加氧酶2的肿瘤细胞具有更强的侵袭性、血管生成能力和细胞凋亡抵抗性，这可能是由于PGE2诱导的血管生成因子表达以及抗凋亡蛋白survivin的稳定化。PGE2 对免疫系统具有混合效应。它在体外抑制T细胞活化，表明它是一种免疫抑制剂。然而，在体内，它影响Th17亚群的扩增和T辅助细胞Th1亚群的分化，表明它是一种免疫激活剂。
体外研究	PGE2 shows inhibition of IL 2 production in the mixture of irradiated and nonirradiated T lymphocytes. PGE2 (0.1-10 μM)dose-dependently inhibits the production of IL 2. PGE2 acts during the inductive phase of activation of suppressor cells.Preincubation of T lymphocytes with PGE2 induces cells that suppress IL 2 production and PHA proliferation.
体内研究	PGE2 (0.3 μg/k, i.p.) significantly reduces the number of peritoneab macrophages undergoing phagocytosis of the methacrybate microbeads in rats. PGE2 (0.1 mg/min, i.a.) increases renal blood flow. PGE2 produces a biphasic change in renal vascular resistance, vasodilatation starts at 0.01 mg/min and is maximal at about 3 mg/min, while at the highest dose used (20 mg/min) PGE2 induces renal vasoconstriction.
特征

推荐实验方法(仅供参考)

细胞实验：
Lymphocytes in CM (1×10⁶ cells/mL) are ditributed in microculture plates (100 μL) in triplicate in the presence of PGEtreated T cells or medium-treated T cells and stimulated with PHA-P at various mitogenic doses. After 72 hr, cultures are pulsed with 1 μCi [3H]thymidine per well (specific activity 5 Ci/mM) for 16 to 18 hr, collected with amicroprecipltator, dried, and counted in a liquid scintillation counter.
动物实验：
Male Sprague Dawley rats (200-250 g) are used throughout the study. For 3 consecutive days rats in the experimental groups receive a daily intraperitoneal injection of either PGE2 (0.3 μg/kg body weight (BW)), the prostaglandin inhibitor mecbofenamate (10 mg/kg BW) or the prostaglandin precursor arachidonic acid (0.3 μg/ kg BW). To determine whether or not 0.3 μg/kg BW of a fatty acid produces nonspecific effects, the biologically inactive fatty acid 11, 14, 17-eicosatrienoic acid is also administered to a group of rats. Rats in the control group receive an equivalent volume (2.0 mL/kg BW) of the vehicle. On the third day, 3 mL of a suspension containing 1.2×10⁶ fluorescent methacrylate microbeads/mL of PBS are injected intraperitoneally (ip) into each rat. Six hours later all animals are given ip a regular dose of their respective treatment. Peritoneal exudate cells are harvested 19-22 hr later.